Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

REPL

Replimune Group Inc

May 22 • 04:00PM ET

5.93

Dollar change +0.36
Percentage change 6.46	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF LABU IWN IBB SCHA VTWO DFAC VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.31	Insider Own	25.94%	Shs Outstand	61.42M	Perf Week	-12.92%
Market Cap	364.22M	Forward P/E	-	EPS next Y	-2.97	Insider Trans	-0.61%	Shs Float	45.48M	Perf Month	-7.63%
Income	-215.79M	PEG	-	EPS next Q	-0.86	Inst Own	91.35%	Short Float	18.61%	Perf Quarter	-25.41%
Sales	0.00M	P/S	-	EPS this Y	0.57%	Inst Trans	-0.78%	Short Ratio	9.00	Perf Half Y	-41.75%
Book/sh	6.10	P/B	0.97	EPS next Y	7.96%	ROA	-38.05%	Short Interest	8.47M	Perf Year	-69.90%
Cash/sh	6.85	P/C	0.87	EPS next 5Y	-	ROE	-46.42%	52W Range	5.47 - 24.81	Perf YTD	-29.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-19.52%	ROI	-48.33%	52W High	-76.10%	Beta	1.17
Dividend TTM	-	Quick Ratio	10.72	Sales past 5Y	0.00%	Gross Margin	-	52W Low	8.41%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	10.72	EPS Y/Y TTM	-6.12%	Oper. Margin	0.00%	RSI (14)	37.97	Volatility	9.35% 7.20%
Employees	331	Debt/Eq	0.20	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.10	Target Price	13.40
Option/Short	Yes / Yes	LT Debt/Eq	0.19	EPS Q/Q	-3.22%	Payout	-	Rel Volume	1.22	Prev Close	5.57
Sales Surprise	-	EPS Surprise	-6.76%	Sales Q/Q	-	Earnings	May 16 BMO	Avg Volume	941.12K	Price	5.93
SMA20	-8.99%	SMA50	-17.32%	SMA200	-46.55%	Trades		Volume	1,158,627	Change	6.46%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-23	Resumed	Piper Sandler	Overweight	$44
Nov-19-21	Initiated	Piper Sandler	Overweight	$52
Oct-15-21	Resumed	BTIG Research	Buy	$60
Nov-17-20	Initiated	BTIG Research	Buy	$60
Nov-02-20	Initiated	Jefferies	Buy	$67
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy	$25 → $54
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral	$25
May-05-20	Initiated	Barclays	Overweight	$21
Sep-04-19	Initiated	ROTH Capital	Buy	$20
Jul-23-19	Initiated	Chardan Capital Markets	Buy	$28
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight	$27 → $26
Jul-08-19	Initiated	H.C. Wainwright	Buy	$26
Apr-25-19	Initiated	Wedbush	Outperform	$24
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	Leerink Partners	Outperform	$25
Aug-14-18	Initiated	JP Morgan	Overweight	$26

Show Previous Ratings

May-16-24 01:53PM	REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024 (InvestorPlace)
08:00AM	Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-07-24 05:00PM	Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Apr-04-24 08:00AM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-26-24 07:30AM	Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions (GlobeNewswire)
09:55AM	Loading…
Mar-11-24 09:55AM	How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17% (Zacks)
Mar-08-24 12:00PM	What Makes Replimune Group, Inc. (REPL) a New Buy Stock (Zacks)
Mar-06-24 08:00AM	Replimune to Present at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-05-24 08:00AM	Replimune to Present at Three Upcoming Investor Conferences (GlobeNewswire)
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Feb-23-24 09:55AM	Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High? (Zacks)
Feb-08-24 08:42AM	Replimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runway (GuruFocus.com)
08:00AM	Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-16-24 03:59AM	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing (PR Newswire) -5.55%
08:00AM	Loading…
Dec-28-23 08:00AM	Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-23 07:32AM	UPDATE 1-Replimune's skin cancer drug fails in mid-stage study (Reuters) -45.21%
07:10AM	CORRECTED-Replimune's skin cancer drug fails in mid-stage study (Reuters)
07:00AM	Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers (GlobeNewswire)
Nov-13-23 09:55AM	Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 (GlobeNewswire)
Nov-08-23 09:10AM	Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research (GlobeNewswire) +6.56%
Nov-07-23 08:00AM	Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -15.85%
Nov-03-23 07:30PM	Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Oct-17-23 03:00AM	Tessellate BIO Emerges from Stealth (GlobeNewswire)
Sep-19-23 04:01PM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Replimune Announces Appointment of Emily Hill as Chief Financial Officer (GlobeNewswire)
Sep-14-23 01:23PM	Insider Sell: Pamela Esposito Sells 5,658 Shares of Replimune Group Inc (GuruFocus.com)
Aug-03-23 08:00AM	Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.69%
Aug-01-23 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Jul-31-23 04:01PM	Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma (Business Wire)
03:57PM	Loading…
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Jul-20-23 08:00AM	Replimune Announces Sander Slootweg will Depart from its Board of Directors (GlobeNewswire) -5.44%
Jun-06-23 10:00AM	Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting (GlobeNewswire)
Jun-05-23 08:00AM	Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors (GlobeNewswire) +19.01%
Jun-03-23 02:15PM	Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Jun-01-23 04:01PM	Replimune to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-25-23 05:00PM	Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-18-23 08:00AM	Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-17-23 10:02AM	Is a Surprise Coming for Replimune (REPL) This Earnings Season? (Zacks) +5.46%
May-09-23 08:00AM	Replimune to Participate in the Piper Sandler Spring Biopharma Symposium (GlobeNewswire)
Mar-31-23 09:35AM	Down -22% in 4 Weeks, Here's Why Replimune Group, Inc. (REPL) Looks Ripe for a Turnaround (Zacks)
Mar-08-23 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Feb-24-23 09:35AM	Replimune Group, Inc. (REPL) Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -11.29%
Feb-09-23 08:50AM	Replimune Group, Inc. (REPL) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) -9.12%
08:00AM	Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-07-23 08:00AM	Replimune to Present at the Virtual SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-06-23 09:55AM	Wall Street Analysts Think Replimune Group, Inc. (REPL) Could Surge 87.88%: Read This Before Placing a Bet (Zacks)
09:04AM	Institutional investors may adopt severe steps after Replimune Group, Inc.'s (NASDAQ:REPL) latest 5.3% drop adds to a year losses (Simply Wall St.)
08:50AM	Recent Price Trend in Replimune Group, Inc. (REPL) is Your Friend, Here's Why (Zacks)
Jan-05-23 05:44AM	The Petri Dish: Fulcrum CEO steps down; Moderna cools on mpox vaccine (American City Business Journals)
Jan-04-23 08:05AM	Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer (GlobeNewswire)
Jan-03-23 08:00AM	Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-14-22 10:46AM	Replimune Breaks Out: Could Rise 30% From Here (TheStreet.com) +5.76%
Dec-12-22 02:36PM	Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform (Benzinga)
Dec-08-22 09:04PM	Replimune Announces Pricing of Public Offering (GlobeNewswire)
Dec-07-22 04:04PM	Replimune Announces Proposed Public Offering (GlobeNewswire) +22.23%
10:05AM	Replimune Shares Surge After Early Data From Pretreated Melanoma Patients (Benzinga)
07:00AM	Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update (GlobeNewswire)
06:30AM	Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma (GlobeNewswire)
Nov-23-22 08:00AM	Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-22-22 08:00AM	Replimune to Host Virtual Investor Event on December 7, 2022 (GlobeNewswire) +5.14%
Nov-03-22 08:00AM	Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 04:01PM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Oct-14-22 01:52PM	Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts (Benzinga) +5.13%
Oct-07-22 08:00AM	Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. (GlobeNewswire)
Aug-24-22 07:58AM	Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks (Motley Fool)
Aug-06-22 09:36AM	Is Replimune Group (NASDAQ:REPL) Using Too Much Debt? (Simply Wall St.)
Aug-04-22 08:00AM	Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-22 04:01PM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Jun-03-22 08:00AM	Replimune Announces the Departure of Jason Rhodes from its Board of Directors (GlobeNewswire) +7.62%
Jun-02-22 08:00AM	Replimune to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-22 06:42AM	Is There An Opportunity With Replimune Group, Inc.'s (NASDAQ:REPL) 38% Undervaluation? (Simply Wall St.)
May-26-22 05:15PM	Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-19-22 08:00AM	Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 08:55AM	10 Best Stocks to Buy Under $20 According to Jeremy Greens Redmile Group (Insider Monkey)
Apr-14-22 01:35PM	We Think Replimune Group (NASDAQ:REPL) Can Afford To Drive Business Growth (Simply Wall St.)
Mar-30-22 07:00AM	Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies (GlobeNewswire)
Mar-21-22 08:00AM	Replimune to Host Virtual Investor Event on March 30, 2022 (GlobeNewswire)
Feb-11-22 08:00AM	Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire)
Feb-03-22 08:00AM	Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-31-22 04:01PM	Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors (GlobeNewswire) +6.56%
Jan-10-22 07:00AM	Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones (GlobeNewswire)
Jan-04-22 08:00AM	Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-21 09:35AM	Is Replimune Group, Inc. (NASDAQ:REPL) Expensive For A Reason? A Look At Its Intrinsic Value (Simply Wall St.)
Dec-08-21 07:38PM	Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ... (GuruFocus.com)
Dec-02-21 08:00AM	Replimune Appoints Christy Oliger to its Board of Directors (GlobeNewswire)
Nov-12-21 07:00AM	Replimune Provides Updated Data from RP2 at the 2021 Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting (GlobeNewswire)
Nov-04-21 08:00AM	Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-21 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Oct-01-21 08:01AM	Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting (GlobeNewswire)
Aug-09-21 09:52AM	We're Not Worried About Replimune Group's (NASDAQ:REPL) Cash Burn (Simply Wall St.)
Aug-06-21 08:00AM	Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update (GlobeNewswire) -10.38%
Aug-02-21 08:00AM	Replimune to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Jul-07-21 08:00AM	Replimune to Present at the William Blair Biotech Focus Conference 2021 (GlobeNewswire)
Jun-03-21 07:00AM	Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1 (GlobeNewswire) -12.00%
May-20-21 08:00AM	Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
May-10-21 08:00AM	Replimune Appoints Tanya Lewis as Chief Development Operations Officer (GlobeNewswire) -5.16%
May-05-21 07:00AM	Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma (GlobeNewswire) +8.79%
Apr-28-21 08:00AM	Replimune to Host Virtual Investor Event on June 3, 2021 (GlobeNewswire) +6.00%

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Astley-Sparke Philip	Executive Chairman	May 16 '24	Sale	6.47	37,928	245,394	1,487,350	May 20 08:04 PM
Patel Sushil	Chief Executive Officer	May 16 '24	Sale	6.47	20,194	130,655	212,014	May 20 08:01 PM
Love Colin	Chief Operating Officer	May 16 '24	Sale	6.47	17,615	113,969	777,345	May 20 08:05 PM
Coffin Robert	Director	May 16 '24	Sale	6.47	11,464	74,172	1,821,872	May 20 08:02 PM
Xynos Konstantinos	Chief Medical Officer	May 16 '24	Sale	6.47	6,367	41,194	133,012	May 20 08:00 PM
Schwendenman Andrew	Chief Accounting Officer	May 16 '24	Sale	6.47	2,298	14,868	38,238	May 20 08:06 PM
Sarchi Christopher	Chief Commercial Officer	May 16 '24	Sale	6.47	2,218	14,350	92,252	May 20 08:06 PM
Xynos Konstantinos	Chief Medical Officer	Nov 16 '23	Sale	10.92	7,313	79,858	112,714	Nov 17 08:01 PM
Sarchi Christopher	Chief Commercial Officer	Nov 16 '23	Sale	10.92	5,255	57,385	72,245	Nov 17 08:00 PM
Esposito Pamela	Chief Business Officer	Sep 12 '23	Option Exercise	3.30	300	990	263,736	Sep 13 09:02 PM
Esposito Pamela	Chief Business Officer	Sep 12 '23	Sale	20.00	300	6,000	263,436	Sep 13 09:02 PM
Esposito Pamela	Chief Business Officer	Sep 11 '23	Option Exercise	3.30	5,358	17,681	268,794	Sep 13 09:02 PM
Esposito Pamela	Chief Business Officer	Sep 11 '23	Sale	20.01	5,358	107,214	263,436	Sep 13 09:02 PM
Esposito Pamela	Chief Business Officer	Aug 22 '23	Option Exercise	6.58	18,600	122,380	282,036	Aug 24 08:30 PM
Esposito Pamela	Chief Business Officer	Aug 22 '23	Sale	20.01	18,600	372,186	263,436	Aug 24 08:30 PM
Esposito Pamela	Chief Business Officer	Aug 11 '23	Option Exercise	3.30	1,400	4,620	264,836	Aug 15 08:30 PM
Esposito Pamela	Chief Business Officer	Aug 11 '23	Sale	20.00	1,400	28,000	263,436	Aug 15 08:30 PM
Esposito Pamela	Chief Business Officer	Jul 10 '23	Option Exercise	6.35	20,000	127,000	283,436	Jul 11 09:00 PM
Esposito Pamela	Chief Business Officer	Jul 10 '23	Sale	21.58	20,000	431,541	263,436	Jul 11 09:00 PM
Lewis Tanya	Chief Dev. Op. Officer	Jun 13 '23	Sale	24.06	12,860	309,395	135,293	Jun 15 09:01 PM
Patel Sushil	Chief Strategy Officer	Jun 13 '23	Sale	24.04	5,698	137,008	148,873	Jun 15 09:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REPL

Replimune Group Inc

Upgrade your FINVIZ experience